Bank of New York Mellon Corp Buys 57,073 Shares of Cerus Co. (NASDAQ:CERS)

Bank of New York Mellon Corp raised its stake in Cerus Co. (NASDAQ:CERS) by 10.2% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 614,446 shares of the biotechnology company’s stock after purchasing an additional 57,073 shares during the period. Bank of New York Mellon Corp’s holdings in Cerus were worth $1,081,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also added to or reduced their stakes in the company. Hood River Capital Management LLC bought a new stake in shares of Cerus in the 1st quarter valued at about $566,000. Wasatch Advisors LP boosted its stake in Cerus by 11.2% in the fourth quarter. Wasatch Advisors LP now owns 6,530,019 shares of the biotechnology company’s stock valued at $14,105,000 after acquiring an additional 656,971 shares in the last quarter. Neuberger Berman Group LLC purchased a new position in Cerus in the fourth quarter worth $26,000. Sumitomo Mitsui Trust Holdings Inc. increased its position in shares of Cerus by 2.4% during the first quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 7,750,700 shares of the biotechnology company’s stock worth $14,649,000 after purchasing an additional 182,629 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its holdings in shares of Cerus by 4.9% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 192,873 shares of the biotechnology company’s stock valued at $365,000 after purchasing an additional 8,982 shares during the last quarter. 78.37% of the stock is currently owned by institutional investors.

Cerus Stock Down 1.6 %

Cerus stock opened at $1.80 on Friday. Cerus Co. has a 1-year low of $1.21 and a 1-year high of $2.59. The business has a fifty day moving average price of $2.19 and a 200-day moving average price of $1.96. The company has a debt-to-equity ratio of 1.29, a current ratio of 2.51 and a quick ratio of 1.83. The stock has a market capitalization of $332.80 million, a price-to-earnings ratio of -10.59 and a beta of 1.19.

Cerus (NASDAQ:CERS) last issued its quarterly earnings results on Thursday, August 1st. The biotechnology company reported ($0.03) earnings per share for the quarter, topping the consensus estimate of ($0.04) by $0.01. Cerus had a negative return on equity of 44.27% and a negative net margin of 14.15%. The business had revenue of $45.08 million during the quarter, compared to the consensus estimate of $42.50 million. During the same quarter last year, the company earned ($0.07) earnings per share. Equities research analysts forecast that Cerus Co. will post -0.13 EPS for the current fiscal year.

Insider Buying and Selling

In other Cerus news, CFO Kevin Dennis Green sold 28,385 shares of the company’s stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $2.18, for a total transaction of $61,879.30. Following the transaction, the chief financial officer now owns 590,365 shares in the company, valued at approximately $1,286,995.70. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other Cerus news, CFO Kevin Dennis Green sold 28,385 shares of the business’s stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $2.18, for a total transaction of $61,879.30. Following the sale, the chief financial officer now owns 590,365 shares in the company, valued at approximately $1,286,995.70. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Richard J. Benjamin sold 21,605 shares of the stock in a transaction dated Friday, August 2nd. The shares were sold at an average price of $2.50, for a total value of $54,012.50. Following the completion of the transaction, the insider now directly owns 438,007 shares in the company, valued at $1,095,017.50. The disclosure for this sale can be found here. 3.40% of the stock is owned by company insiders.

Cerus Company Profile

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.